ALTB-268

BIOLOGICAL3 trials

Sponsors

AltruBio Inc.

Conditions

Healthy VolunteersUlcerative ColitisUlcerative Colitis (UC)

Phase 1

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

CompletedNCT05723692

AltruBio Inc.Healthy Volunteers

Start: 2023-01-17End: 2023-10-27Updated: 2024-02-06

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

Active, not recruitingNCT07350577

AltruBio Inc.Ulcerative Colitis (UC)

Start: 2025-11-17End: 2026-09-28Target: 24Updated: 2026-05-01

Phase 2

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Active, not recruitingNCT06109441

AltruBio Inc.Ulcerative Colitis

Start: 2023-12-04End: 2028-03-01Target: 50Updated: 2026-05-05